论文部分内容阅读
目的评价匹伐他汀钙片治疗高胆固醇血症的有效性和安全性。方法 360例高胆固醇血症患者按1:1:1比例随机分为匹伐他汀钙片1 mg组、2 mg组和阿托伐他汀钙片10 mg组,经4周筛选期后,符合入选标准的患者接受1 mg、2 mg匹伐他汀钙片或10 mg阿托伐他汀钙片治疗(一日1次,口服),治疗8周,观察各组治疗前后血清低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)和甘油三酯(TG)变化情况。结果治疗8周后各组LDL-C下降显著,分别为-30.06%、-35.04%和-34.34%,组间差异无统计学意义。匹伐他汀钙片2 mg组降低LDL-C的疗效非劣于阿托伐他汀钙片组,匹伐他汀钙片1 mg组降低LDL-C的疗效劣于阿托伐他汀钙片组。治疗4、8周后匹伐他汀钙降低TC、HDL-C和TG作用与阿托伐他汀钙比较差异无统计学意义。结论匹伐他汀钙片治疗高胆固醇血症安全有效。
Objective To evaluate the efficacy and safety of pitavastatin calcium in the treatment of hypercholesterolemia. Methods One hundred and sixty patients with hypercholesterolemia were randomly divided into 1 mg of pitavastatin calcium tablets, 2 mg of atavastatin and 10 mg of atorvastatin calcium tablets according to the ratio of 1: 1: 1. After 4 weeks of screening, they were eligible Standard patients received 1 mg, 2 mg pitavastatin calcium tablets or 10 mg atorvastatin calcium tablets (once a day orally) for 8 weeks. The levels of serum low density lipoprotein cholesterol (LDL -C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and triglyceride (TG). Results After 8 weeks of treatment, the LDL-C in each group decreased significantly, which were -30.06%, -35.04% and -34.34%, respectively. There was no significant difference between the two groups. Pitavastatin calcium 2 mg group reduced LDL-C efficacy is not inferior to atorvastatin calcium group, pitavastatin calcium 1 mg group lower LDL-C efficacy than atorvastatin calcium group. After 4 and 8 weeks of treatment, the effect of lowering the TC, HDL-C and TG of pitavastatin calcium was not statistically different from that of atorvastatin calcium. Conclusion Pitavastatin calcium is safe and effective in treating hypercholesterolemia.